Clinical outcomes for immune checkpoint inhibitors plus chemotherapy in non-small-cell lung cancer patients with uncommon driver gene alterations.

BMC Cancer · 2024 · PMC11297614 · PMID 39097705

Europe PMC DOI

hedged sentence

0.1280

closest p · 2.6× alpha

0.1280

boldest claim

The sentences

did not reach statistical significancep = 0.128not close (p > 0.1)

Compared with patients with RET -altered NSCLC who did not receive RET-TKIs, those who received RET-TKIs have a trend of OS difference, but the difference did not reach statistical significance (NR vs 35 months, p = 0.128; Figure S2).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.